On 1 May, the Medicare Benefits Schedule (MBS) indications for an Interferon Gamma Release Assay (IGRA) (e.g. Quantiferon Gold) were expanded to include (along with other conditions) people who have been exposed to a confirmed case of active tuberculosis (TB).
The history of TB exposure does not need to be recent nor microbiologically confirmed. This particular indication will likely cover people of refugee-background who have typically been subject to high TB-risk environments. Screening for latent and active TB is a standard component of the initial Refugee Health Assessment for refugees and asylum seekers upon arrival in Australia. This change in MBS eligibility will greatly facilitate completion of this assessment. For more information, please see the Australian Department of Health website.
Disclaimer: This article was provided by Department of Health. While every effort has been made to ensure the information is accurate, North Western Melbourne Primary Health Network does not warrant or represent the accuracy, currency and completeness of any information or material included within.
